Clinical Trial Update: Oral Sirolimus for In-Stent Restenosis [Phase 4]

View source ↗

Summary

Phase 4 trial of oral sirolimus for preventing in-stent restenosis in patients with coronary restenosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Restenosis

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Deutsches Herzzentrum Muenchen | Conditions: Coronary Restenosis | Phase 4 | Status: COMPLETED